Indian generic giants to get easier access to Korean pharmaceutical market

Published: 2010-07-26 07:00:00

Updated: 2010-07-26 07:00:00

Influenced by the government’s firm determination to stamp out illegal rebate here, Indian generic markers are poised to enter the Korean pharmaceutical market as situation will permit.

"If Cipla makes good business success in Korea with more than 100 generic products, other top generic drug c...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK